APA (7th ed.) Citation

AJ, N., T, S., AAZ, T., RN, K., PD, T., SN, A., . . . SS, L. (2023). SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis. Molecular cancer, 22(1), 52. https://doi.org/10.1186/s12943-023-01734-w

Chicago Style (17th ed.) Citation

AJ, Njouendou, et al. "SOX2 Dosage Sustains Tumor-promoting Inflammation to Drive Disease Aggressiveness by Modulating the FOSL2/IL6 Axis." Molecular Cancer 22, no. 1 (2023): 52. https://doi.org/10.1186/s12943-023-01734-w.

MLA (9th ed.) Citation

AJ, Njouendou, et al. "SOX2 Dosage Sustains Tumor-promoting Inflammation to Drive Disease Aggressiveness by Modulating the FOSL2/IL6 Axis." Molecular Cancer, vol. 22, no. 1, 2023, p. 52, https://doi.org/10.1186/s12943-023-01734-w.